Archive

ECCO 2016: Mechanisms by which inflammation resolves

Silvio Danese, Humanitas Clinical and Research Hospital, Milan, Italy. Article by Maria Dalby – The current paradigm for managing inflammatory conditions is to suppress the inflammatory response by… read more.

ECCO 2016: IOIBD: Disease severity definition in IBD. Professor Laurent Peyrin-Biroulet (Nancy University Hospital, France) discusses a new disease severity score initiated by the IOIBD

ECCO 2016: Dr Charlie Lees (Edinburgh, UK), Dr Ailsa Hart and Marian O’Connor (Harrow, UK), Dr James Lindsay (London, UK) and Dr Peter Irving (London, UK) discuss the new therapeutic landscape in IBD since changes to guidance by NICE and SMC over the last year

New drugs in IBD – by Maria Dalby Tofacitinib Two randomised placebo-controlled phase 3 studies (OCTAVE Induction 1 and 2) show that tofacitinib, an oral small-molecule Janus kinase… read more.

ECCO 2016: Professor Jean-Frederic Colombel (New York, USA) and Dr James Lindsay (Barts and the London NHS Trust, UK) discuss new data from the GEMINI programme showing patient populations that do well and long term data with vedolizumab

Update from the GEMINI study programme – by Maria Dalby Jean-Frédéric Colombel, Mount Sinai Hospital, New York, USA The GEMINI study programme is a large phase-3 clinical trial… read more.

ECCO 2016: Dr Charlie Lees (Edinburgh, UK) discusses in the video and article below the factors influencing the decision to stop treatment and discussed whether it may be possible to predict relapse using currently available methods

Stopping drugs – by Maria Dalby Charles Lees (Edinburgh, UK) Medication constitutes a large part of the IBD exposome, and stopping drug treatment should be a therapeutic goal… read more.

ECCO 2016: Professor David Rubin from Chicago discusses the challenges of UC management and optimising biological therapy

Management of ulcerative colitis: putting patients at the centre – by Maria Dalby Iris Dotan (Tel Aviv Sourasky Medical Centre, Israel), Peter Irving (Guy’s and St Thomas’ NHS… read more.

ECCO 2016: Professor Séverine Vermeire (Leuven, Belgium) discusses new patient guidelines for Crohn’s disease and ulcerative colitis which were released at this year’s 11th Congress of ECCO in Amsterdam, and Helen Terry (CCUK) discusses how they might be rolled out to patients in the UK.

ECCO-EFCCA Patient Guidelines – by Maria Dalby Marco Greco, Milan, Italy; Séverine Vermeire, University Hospital of Leuven, Belgium; Salvatore Leone, Palermo, Italy; Paolo Gionchetti, University of Bologna, Italy; Martin Kojinov, Sofia, Bulgaria; Axel… read more.

ECCO 2016: Professor Laurent Peyrin-Biroulet (Nancy, France), Professor Jean-Frederic Colombel (New York, USA), Marian O’Connor (Harrow, UK) and Dr Charlie Lees (Edinburgh, UK) give their highlights of the 11th Congress of ECCO

UEGW 2015: Management of IBD after anti-TNF failure. Professor Laurent Peyrin-Biroulet (Nancy, France) discusses his presentation on when to use anti-integrins or anti-TNFs and the iCARE programme sponsored by ECCO.

by Maria Dalby: Managing patients with active disease who fail to respond to anti-TNF therapy remains a key unmet need in IBD. Introducing a free paper session on… read more.

Physical activity reduces breast cancer risk

Practising sport for more than an hour day reduces the risk of contracting breast cancer, and this applies to women of any age and any weight, and also… read more.

Poster Session at ECC 2013 – Circulating tumour cell counts in advanced and metastatic colorectal cancer by immunomagnetic labelling: Results reflect the reality?

Solange M Sanches et al, AC Camargo Cancer Center, São Paulo, Brazil.

Poster Session at ECC 2013 – Younger patients at high risk

Discussion of the abstract by Dr Christopher Lieu, MD, Assistant professor at the University of Colorado.  Younger patients with colorectal cancer that has spread (metastasised) to other parts… read more.